SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round.